Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M117,938Revenue $M44,175Net Margin (%)20.5Z-Score2.4
Enterprise Value $M143,776EPS $3.7Operating Margin %26.5F-Score7
P/E(ttm))15.0Cash Flow Per Share $0Pre-tax Margin (%)25.1Higher ROA y-yY
Price/Book11.510-y EBITDA Growth Rate %3.0Quick Ratio0.8Cash flow > EarningsY
Price/Sales2.95-y EBITDA Growth Rate %2.6Current Ratio1.1Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-11.2ROA % (ttm)12.9Higher Current Ratio y-yY
Dividend Yield %5.4Insider Buy (3m)0ROE % (ttm)77.7Less Shares Outstanding y-yY
Payout Ratio %81.0Shares Outstanding M2,427ROI % (ttm)14.0Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKCharles Brandes 2014-06-30 Add0.21%$51.55 - $56.39
($54.16)
$ 49.1-9%Add 15.52%2,500,048
GSKJames Barrow 2014-06-30 Buy 0.02%$51.55 - $56.39
($54.16)
$ 49.1-9%New holding, 270900 sh.270,900
GSKPRIMECAP Management 2014-06-30 Reduce-0.25%$51.55 - $56.39
($54.16)
$ 49.1-9%Reduce -43.82%5,156,449
GSKJohn Hussman 2014-03-31 Reduce-0.38%$50.9 - $56.66
($54)
$ 49.1-9%Reduce -23.61%323,500
GSKVanguard Health Care Fund 2014-03-31 Sold Out -0.11%$50.9 - $56.66
($54)
$ 49.1-9%Sold Out0
GSKJohn Hussman 2013-12-31 Add1.51%$49.31 - $53.68
($51.87)
$ 49.1-5%Add 1702.13%423,500
GSKCharles Brandes 2013-12-31 Add0.16%$49.31 - $53.68
($51.87)
$ 49.1-5%Add 13.11%2,145,461
GSKJoel Greenblatt 2013-12-31 Buy 0.11%$49.31 - $53.68
($51.87)
$ 49.1-5%New holding, 83452 sh.83,452
GSKVanguard Health Care Fund 2013-12-31 Reduce-0.14%$49.31 - $53.68
($51.87)
$ 49.1-5%Reduce -55.18%644,881
GSKWarren Buffett 2013-12-31 Sold Out -0.02%$49.31 - $53.68
($51.87)
$ 49.1-5%Sold Out0
GSKWarren Buffett 2013-09-30 Reduce-0.06%$50.27 - $52.96
($51.54)
$ 49.1-5%Reduce -76.57%345,819
GSKJoel Greenblatt 2013-06-30 Sold Out -0.16%$46.79 - $53.59
($50.77)
$ 49.1-3%Sold Out0
GSKVanguard Health Care Fund 2013-06-30 Reduce-0.1%$46.79 - $53.59
($50.77)
$ 49.1-3%Reduce -26.11%1,611,181
GSKJean-Marie Eveillard 2013-06-30 Reduce-0.05%$46.79 - $53.59
($50.77)
$ 49.1-3%Reduce -100%1
GSKJohn Hussman 2013-03-31 Reduce-0.57%$43.47 - $46.91
($44.97)
$ 49.19%Reduce -95.51%23,500
GSKVanguard Health Care Fund 2013-03-31 Reduce-0.07%$43.47 - $46.91
($44.97)
$ 49.19%Reduce -20.49%2,180,381
GSKJohn Hussman 2012-12-31 Add0.58%$41.9 - $47.45
($44.3)
$ 49.111%Add 2584.62%523,500
GSKDodge & Cox 2012-12-31 Add0.18%$41.9 - $47.45
($44.3)
$ 49.111%Add 5.08%63,302,825
GSKTweedy Browne 2012-12-31 Add0.03%$41.9 - $47.45
($44.3)
$ 49.111%Add 20.16%151,264
GSKJoel Greenblatt 2012-12-31 Reduce-0.09%$41.9 - $47.45
($44.3)
$ 49.111%Reduce -32.53%60,720
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
GSK James Barrow 2014-06-30270,9000.010.02New Buy
GSK Charles Brandes 2014-06-302,500,0480.11.6+15.52%
GSK Joel Greenblatt 2014-06-3083,52800.06+0.09%
GSK Jean-Marie Eveillard 2014-06-30100
GSK John Hussman 2014-06-30323,5000.011.3
GSK Dodge & Cox 2014-06-3060,226,0502.483.1-0.27%
GSK Tweedy Browne 2014-06-30142,1180.010.16-0.34%
GSK PRIMECAP Management 2014-06-305,156,4490.210.3-43.82%
Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12309.17view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14250.71view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12309.17view

Press Releases about GSK :

    Quarterly/Annual Reports about GSK:

      News about GSK:

      Articles On GuruFocus.com
      3 Dividend Kings From The U.K. I Love To Buy Aug 21 2014 
      Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG Aug 18 2014 
      You Should Consider Adding GlaxoSmithKline Based on Tremendous ROE Aug 08 2014 
      Widely Held Guru Stocks Near 52-Week Lows Aug 05 2014 
      Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, UBS Aug 04 2014 
      A Look at the Week's Top Dividend Growers Jul 28 2014 
      Highest Yielding Stocks Widely Held By The Gurus Jul 01 2014 
      Diamond Hill Capital Comments on GlaxoSmithKline PLC Jun 26 2014 
      Major British Companies Lead Top Guru-Held UK and Ireland Stocks Jun 10 2014 
      Can Pfizer Make Up Its Loss? May 09 2014 

      More From Our Partners
      Markets Reverse Early Morning Losses; Still Lower On The Day Aug 28 2014 - BENZINGA

      More From Other Websites
      [video] Human trials of Ebola Vaccine Aug 29 2014
      [video] Human Trials of an Ebola Vaccine Launch Aug 28 2014
      [video] Ebola response roadmap Aug 28 2014
      [video] GlaxoSmithKline Ebola Vaccine Being Fast-Tracked for Human Trials Aug 28 2014
      Use caution when investing in Ebola-related stocks Aug 28 2014
      [video] Stocks Weighed by Ukraine Crisis Overtaking Positive Economic Data Aug 28 2014
      Why GlaxoSmithKline (GSK) Stock Is Gaining Today Aug 28 2014
      Glaxo's Promacta Label Now Includes Severe Aplastic Anemia Aug 27 2014
      GSK receives FDA approval of an additional Promacta® (eltrombopag) indication for use in patients... Aug 26 2014
      The Benefits Of Investing In GlaxoSmithKline plc Aug 26 2014
      ViiV Healthcare's Single-Pill HIV Drug Triumeq Cleared by FDA Aug 25 2014
      [video] Jim Cramer Says Roche's "Bolt-On" Acquisition Means Big Pharma is Thinking Big Aug 25 2014
      InterMune Stock Spikes On Rare Big Biotech Buyout Aug 25 2014
      Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir,... Aug 25 2014
      ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new... Aug 22 2014
      Here’s Why You Need GlaxoSmithKline plc In Your Portfolio Aug 22 2014
      GlaxoSmithKline's (GSK) Arnuity Ellipta Approved by FDA Aug 21 2014
      GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the US for the treatment... Aug 20 2014
      GlaxoSmithKline plc Could Be Worth 1690p! Aug 20 2014
      The Warren Buffett Guide to Making Money Aug 19 2014

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK